Rapid Identification of Fungi by Using the ITS2 Genetic Region and an Automated Fluorescent Capillary Electrophoresis System

Invasive fungal disease often plays an important role in the morbidity and mortality of immunocompromised patients. The poor sensitivity of current fungal blood culture and histological practices has led to the development of highly sensitive and specific molecular techniques, such as the PCR. Sequence variability of the internal transcribed spacer 2 (ITS2) region of fungi is potentially useful in rapid and accurate diagnosis of clinical fungal isolates. PCR with fungus-specific primers targeted toward conserved sequences of the 5.8S and 28S ribosomal DNA (rDNA) results in amplification of the species-specific ITS2 regions, which are variable in amplicon length. We have made use of the ABI PRISM 310 genetic analyzer and the ABI PRISM 310 GeneScan analysis software for the determination of variable size differences of the ITS2 region of clinically important fungi, including Candida and non-Candida yeasts, Aspergillus species, and a variety of dermatophytes. No cross-reaction occurred when samples were tested against human and bacterial genomic DNA. We have found that most clinically significant fungal isolates can be differentiated by this method, and it therefore serves to be a promising tool for the rapid (<7 h) diagnosis of fungemia and other invasive fungal infections.

[1]  E. Tronci,et al.  1996 , 1997, Affair of the Heart.

[2]  H. Lankinen,et al.  Acute-Phase-Specific Hepatapeptide Epitope for Diagnosis of Parvovirus B19 Infection , 2000, Journal of Clinical Microbiology.

[3]  S. Sanche,et al.  Rapid Identification of Fungi by Using the ITS2 Genetic Region and an Automated Fluorescent Capillary Electrophoresis System , 1999, Journal of Clinical Microbiology.

[4]  T. Lott,et al.  Rapid Identification of Candida Species with Species-Specific DNA Probes , 1998, Journal of Clinical Microbiology.

[5]  R. Bowden,et al.  Panfungal PCR Assay for Detection of Fungal Infection in Human Blood Specimens , 1998, Journal of Clinical Microbiology.

[6]  J. Karlowsky,et al.  Candidemia in a Canadian tertiary care hospital from 1976 to 1996. , 1997, Diagnostic microbiology and infectious disease.

[7]  F. Nolte,et al.  Rapid identification of Candida species in blood cultures by a clinically useful PCR method , 1997, Journal of clinical microbiology.

[8]  D. Pittet,et al.  Microbiological factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  H. Einsele,et al.  Detection and identification of fungal pathogens in blood by using molecular probes , 1997, Journal of clinical microbiology.

[10]  M. Nucci,et al.  Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  M. Nasu,et al.  PCR detection of DNA specific for Aspergillus species in serum of patients with invasive aspergillosis , 1996, Journal of clinical microbiology.

[12]  D. Snydman,et al.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. , 1996, The American journal of medicine.

[13]  G. Roberts,et al.  Molecular probes for diagnosis of fungal infections , 1995, Journal of clinical microbiology.

[14]  D. Williams,et al.  Identification of Candida species by PCR and restriction fragment length polymorphism analysis of intergenic spacer regions of ribosomal DNA , 1995, Journal of clinical microbiology.

[15]  T. Lott,et al.  Microtitration plate enzyme immunoassay to detect PCR-amplified DNA from Candida species in blood , 1995, Journal of clinical microbiology.

[16]  J. Rex,et al.  Resistance of Candida species to fluconazole , 1995, Antimicrobial agents and chemotherapy.

[17]  M. Larocco,et al.  Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period , 1994, Antimicrobial Agents and Chemotherapy.

[18]  R. Kuykendall,et al.  Nucleotide sequence analysis of the 5·8S rDNA and adjacent ITS2 region of Candida albicans and related species , 1993, Yeast.

[19]  H. Horowitz,et al.  Fluconazole Prophylaxis of Fungal Infections in Patients with Acute Leukemia: Results of a Randomized Placebo-Controlled, Double-Blind, Multicenter Trial , 1993, Annals of Internal Medicine.

[20]  J. L. Goodman,et al.  A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. , 1992, The New England journal of medicine.

[21]  E. Reed,et al.  Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. , 1991, The Journal of infectious diseases.

[22]  T. Walsh,et al.  Distinction of deep versus superficial clinical and nonclinical isolates of Trichosporon beigelii by isoenzymes and restriction fragment length polymorphisms of rDNA generated by polymerase chain reaction , 1991, Journal of clinical microbiology.

[23]  Henry D. Isenberg,et al.  Manual of Clinical Microbiology , 1991 .

[24]  P. Lipke,et al.  Evidence that Candida stellatoidea type II is a mutant of Candida albicans that does not express sucrose-inhibitable alpha-glucosidase , 1990, Infection and immunity.

[25]  T. White Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics , 1990 .

[26]  T. Shawker,et al.  Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. , 1988, Annals of internal medicine.

[27]  Yvonne M Clayton,et al.  Book Review: Medically Important Fungi: A Guide to Identification , 1977 .